Berry-Kravis E - Search Results

1

Yu TW, Berry-Kravis E. Yu TW, et al. Semin Neurol. 2014 Jul;34(3):258-65. doi: 10.1055/s-0034-1386764. Epub 2014 Sep 5. Semin Neurol. 2014. PMID: 25192504 Review.

2

Cyclic AMP metabolism in fragile X syndrome.

Berry-Kravis E, Huttenlocher PR. Berry-Kravis E, et al. Ann Neurol. 1992 Jan;31(1):22-6. doi: 10.1002/ana.410310105. Ann Neurol. 1992. PMID: 1371909

3

Demonstration of abnormal cyclic AMP production in platelets from patients with fragile X syndrome.

Berry-Kravis E, Sklena P. Berry-Kravis E, et al. Am J Med Genet. 1993 Jan 1;45(1):81-7. doi: 10.1002/ajmg.1320450120. Am J Med Genet. 1993. PMID: 8380312

4

Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease.

Bennett DA, Wilson RS, Schneider JA, Evans DA, Aggarwal NT, Arnold SE, Cochran EJ, Berry-Kravis E, Bienias JL. Bennett DA, et al. Neurology. 2003 Jan 28;60(2):246-52. doi: 10.1212/01.wnl.0000042478.08543.f7. Neurology. 2003. PMID: 12552039

5

Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation.

Berry-Kravis E, Potanos K, Weinberg D, Zhou L, Goetz CG. Berry-Kravis E, et al. Ann Neurol. 2005 Jan;57(1):144-7. doi: 10.1002/ana.20360. Ann Neurol. 2005. PMID: 15622531

6

Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS).

Hall DA, Berry-Kravis E, Jacquemont S, Rice CD, Cogswell J, Zhang L, Hagerman RJ, Hagerman PJ, Leehey MA. Hall DA, et al. Neurology. 2005 Jul 26;65(2):299-301. doi: 10.1212/01.wnl.0000168900.86323.9c. Neurology. 2005. PMID: 16043804

7

Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial.

Berry-Kravis E, Krause SE, Block SS, Guter S, Wuu J, Leurgans S, Decle P, Potanos K, Cook E, Salt J, Maino D, Weinberg D, Lara R, Jardini T, Cogswell J, Johnson SA, Hagerman R. Berry-Kravis E, et al. J Child Adolesc Psychopharmacol. 2006 Oct;16(5):525-40. doi: 10.1089/cap.2006.16.525. J Child Adolesc Psychopharmacol. 2006. PMID: 17069542 Clinical Trial.

8

Neuropathic features in fragile X premutation carriers.

Berry-Kravis E, Goetz CG, Leehey MA, Hagerman RJ, Zhang L, Li L, Nguyen D, Hall DA, Tartaglia N, Cogswell J, Tassone F, Hagerman PJ. Berry-Kravis E, et al. Am J Med Genet A. 2007 Jan 1;143A(1):19-26. doi: 10.1002/ajmg.a.31559. Am J Med Genet A. 2007. PMID: 17152065

9

Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines.

Berry-Kravis E, Abrams L, Coffey SM, Hall DA, Greco C, Gane LW, Grigsby J, Bourgeois JA, Finucane B, Jacquemont S, Brunberg JA, Zhang L, Lin J, Tassone F, Hagerman PJ, Hagerman RJ, Leehey MA. Berry-Kravis E, et al. Mov Disord. 2007 Oct 31;22(14):2018-30, quiz 2140. doi: 10.1002/mds.21493. Mov Disord. 2007. PMID: 17618523 Review.

10

Characterization of potential outcome measures for future clinical trials in fragile X syndrome.

Berry-Kravis E, Sumis A, Kim OK, Lara R, Wuu J. Berry-Kravis E, et al. J Autism Dev Disord. 2008 Oct;38(9):1751-7. doi: 10.1007/s10803-008-0564-8. Epub 2008 Mar 28. J Autism Dev Disord. 2008. PMID: 18369716

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

366 results

Search Page

Filters